Table 2.
CRS-207 Clinical and Immune Response Summary
| ≥15 mos OS | ID | Cancer | Dose Level | LLO Response | Mesotheli n Response | RECIST | Survival (mos) | Prior immunoth erapy |
|---|---|---|---|---|---|---|---|---|
| 001-001 | PDA | 10^8 | Yes | No | PD | 15 | GVAX | |
| 001-002 | PDA | 10^8 | Yes | NE | SD | 30+ | GVAX IFN-beta gene | |
| 003-001 | Meso | 10^8 | Yes | Yes | SD | 29+ | transfer1 | |
| 005-002 | NSCLC | 3×10^8 | NE | NE | NE | 23 | No | |
| 004-002 | PDA | 10^9 | Yes | No | SD | 17 | GVAX | |
| 005-001 | NSCLC | 10^9 | Yes | Yes | SD | 26+ | No |
| <15 mos OS | ID | Cancer | Dose Level | LLO Response | Mesotheli n Response | RECIST | Survival (mos) | Prior immunoth erapy |
|---|---|---|---|---|---|---|---|---|
| 002-001 | Ovarian | 10^8 | NE | NE | PD | 22 | No | |
| 002-002 | Meso | 10^8 | NE | NE | PD | 4 | No | |
| 004-001 | Meso | 10^8 | No | No | PD | 5 | No | |
| 001-004 | PDA | 3×10^8 | NE | Yes | PD | 3 | No | |
| 001-005 | PDA | 3×10^8 | NE | Yes | NE | 3 | No | |
| 005-003 | PDA | 3×10^8 | NE | No | NE | 7 | No | |
| 001-003 | PDA | 10^9 | NE | Yes | PD | 7 | No | |
| 002-003 | NSCLC | 10^9 | Yes | NE | PD | 5 | No | |
| 002-004 | Meso | 10^9 | NE | NE | PD | 1 | No IFN-beta gene | |
| 003-002 | Ovarian | 10^9 | No | Yes | PD | 4 | transfer1 | |
| 003-003 | Meso | 10^10 | NE | NE | NE | 5 | No |
1
adenovirus-mediated IFN-beta gene transfer
2
censored due to subject withdrawal of consent.
Abbreviations: LLO, Listeriolysin O; PDA, pancreatic ductal adenocarinoma; Meso, mesothelioma; NE, not evaluable; GVAX (GM-CSF-based whole cell vaccine); + refers to subjects alive as of 10/14/2010. Survival reported as of October 14, 2010.